ATAI Life Sciences BV (ATAI)vsVertex Pharmaceuticals Inc (VRTX)
ATAI
ATAI Life Sciences BV
$3.95
-12.22%
HEALTHCARE · Cap: $1.67B
VRTX
Vertex Pharmaceuticals Inc
$446.83
+1.24%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 350187% more annual revenue ($12.22B vs $3.49M). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
ATAI
Avoid15
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.5%
Fair Value
$8.72
Current Price
$3.95
$4.77 discount
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -378.0% — below average capital efficiency
Revenue declined 38.7%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ATAI
The strongest argument for ATAI centers on Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : ATAI
The primary concerns for ATAI are Market Cap, Profit Margin, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ATAI profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
ATAI carries more volatility with a beta of 1.60 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 15/100), backed by strong 35.5% margins. ATAI offers better value entry with a 54.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ATAI Life Sciences BV
HEALTHCARE · BIOTECHNOLOGY · USA
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?